非構造タンパク質4B(NS4B):治療薬開発パイプライン動向(2016年下半期版)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:DATA70209407)
◆英語タイトル:Nonstructural Protein 4B (NS4B) - Pipeline Review, H2 2016
◆発行会社/調査会社:Global Markets Direct
◆商品コード:DATA70209407
◆発行日:2016年12月28日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
Site LicenseUSD7,000 ⇒換算¥763,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD10,500 ⇒換算¥1,144,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[非構造タンパク質4B(NS4B):治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における 非構造タンパク質4B(NS4B)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・ 非構造タンパク質4B(NS4B)の概要
・ 非構造タンパク質4B(NS4B)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ 非構造タンパク質4B(NS4B)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・ 非構造タンパク質4B(NS4B)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ 非構造タンパク質4B(NS4B)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Nonstructural Protein 4B (NS4B) – Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Nonstructural Protein 4B (NS4B) – Pipeline Review, H2 2016’, provides in depth analysis on Nonstructural Protein 4B (NS4B) targeted pipeline therapeutics.

The report provides comprehensive information on the Nonstructural Protein 4B (NS4B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nonstructural Protein 4B (NS4B)
- The report reviews Nonstructural Protein 4B (NS4B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nonstructural Protein 4B (NS4B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nonstructural Protein 4B (NS4B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nonstructural Protein 4B (NS4B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nonstructural Protein 4B (NS4B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nonstructural Protein 4B (NS4B) Overview 6
Therapeutics Development 7
Nonstructural Protein 4B (NS4B) – Products under Development by Stage of Development 7
Nonstructural Protein 4B (NS4B) – Products under Development by Therapy Area 8
Nonstructural Protein 4B (NS4B) – Products under Development by Indication 9
Nonstructural Protein 4B (NS4B) – Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Nonstructural Protein 4B (NS4B) – Products under Development by Companies 12
Nonstructural Protein 4B (NS4B) – Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Nonstructural Protein 4B (NS4B) – Companies Involved in Therapeutics Development 20
Gilead Sciences Inc 20
GlaxoSmithKline Plc 21
Inovio Pharmaceuticals Inc 22
Johnson & Johnson 23
Merck & Co Inc 24
Nonstructural Protein 4B (NS4B) – Drug Profiles 25
GSK-8853 – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
INO-8000 – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
PTC-512 – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
PTC-725 – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
PTC-971 – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
RL-15A – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Inhibit NS4B Protein for HCV – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Nonstructural Protein 4B (NS4B) – Dormant Projects 34
Nonstructural Protein 4B (NS4B) – Discontinued Products 35
Nonstructural Protein 4B (NS4B) – Featured News & Press Releases 36
Apr 27, 2016: Inovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial 36
Oct 21, 2013: Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial 36
Jan 09, 2013: Inovio Pharma To Initiate Clinical Trial For Hepatitis C Therapeutic Vaccine 37
Oct 26, 2009: Wellcome Trust funds dengue fever research in Leuven 38
Aug 10, 2009: PTC Therapeutics Announced Achievement Of Major Milestone In Schering-Plough Hepatitis C Collaboration 39
Mar 20, 2006: Schering-Plough And PTC Therapeutics Announced Collaboration For Development Of PTC’s Preclinical Hepatitis C Compounds 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Gilead Sciences Inc, H2 2016 20
Pipeline by GlaxoSmithKline Plc, H2 2016 21
Pipeline by Inovio Pharmaceuticals Inc, H2 2016 22
Pipeline by Johnson & Johnson, H2 2016 23
Pipeline by Merck & Co Inc, H2 2016 24
Dormant Projects, H2 2016 34
Discontinued Products, H2 2016 35

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Actions, H2 2016 15
Number of Products by Routes of Administration, H2 2016 16
Number of Products by Stage and Routes of Administration, H2 2016 16
Number of Products by Molecule Types, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 18

*** レポートのキーワード ***

非構造タンパク質4B(NS4B)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • Claude Anne de Solene S.A.R.L – 企業概要
    WMI's 'Claude Anne de Solene S.A.R.L - Company Capsule' is a crucial resource for industry executives and anyone looking to access key information about 'Claude Anne de Solene S.A.R.L '. WMI's 'Claude Anne de Solene S.A.R.L - Company Capsule' report utilizes a wide range of primary and secondary sou …
  • 建設市場レポート:ポルトガル – 主要動向と市場機会
    The Portuguese construction industry valued EUR21.9 billion (US$28.2 billion) in 2012, recording a CAGR of -9.71% during the review period. All construction categories registered negative growth during this period. This is largely a result of economic deceleration following the financial crisis and …
  • 世界のアルコールエトキシレート(AE)市場2016
    Notes:Production, means the output of Alcohol Ethoxylates (AE) Revenue, means the sales value of Alcohol Ethoxylates (AE) This report studies Alcohol Ethoxylates (AE) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global …
  • 頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma):治療薬開発パイプライン動向2015
    SUMMARY DelveInsight’s,“ Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Rec …
  • 世界及び中国の獣医手術用器具市場2017
    The 'Global and Chinese Veterinary Surgical Instruments Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Veterinary Surgical Instruments industry with a focus on the Chinese market. The report provides key statistics on the market st …
  • 韓国の心臓血管外科処置動向(~2020)
    South Korea Cardiovascular Surgery Procedures Outlook to 2020 Summary GlobalData’s new report, "South Korea Cardiovascular Surgery Procedures Outlook to 2020", provides key procedures data on the South Korea Cardiovascular Surgery. The report provides procedure volumes within market categories - Cor …
  • 世界及び中国のP-アミノフェノール市場2018
    The 'Global and Chinese P-Aminophenol Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global P-Aminophenol industry with a focus on the Chinese market. The report provides key statistics on the market status of the P-Aminophenol manufactur …
  • マレーシアの防衛市場:購買・調達ダイナミズム
    Synopsis This report provides in-depth information on the dynamics of Malaysia defense procurement and trend analysis of imports and exports. The figures are based on trend indicator values (TIV) expressed in US$ million at constant (1990) prices. Although figures are expressed in US$, TIVs do not r …
  • BCP/ROA – 210 Livingston Street Mixed-use Tower – New York:建設プロジェクト概要
    World Market Intelligence's "BCP/ROA – 210 Livingston Street Mixed-use Tower – New York - Construction Project Profile" is a crucial resource for industry executives and anyone looking to access key information about the BCP/ROA – 210 Livingston Street Mixed-use Tower – New York construction project …
  • ソフトドリンク(飲料)市場(~2017):ベリーズ
    Synopsis "Soft Drinks Market in Belize: Databook to 2017" is the result of Canadean’s extensive market research covering the Soft Drinks market in Belize. The report presents detailed historic and forecast data on the Soft Drinks consumption trends in Belize, offering consumption volume and value at …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA70209407 )"非構造タンパク質4B(NS4B):治療薬開発パイプライン動向(2016年下半期版)" (英文:Nonstructural Protein 4B (NS4B) - Pipeline Review, H2 2016)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。